BCL2抑制剂维奈克拉联合他莫昔芬治疗ER和BCL2阳性转移性乳腺癌的Ib期剂量递增与扩展研究
这项Ib期3+3剂量递增与扩展研究纳入33例ER和BCL2阳性转移性乳腺癌患者,接受每日他莫昔芬20 mg联合维奈克拉200-800 mg治疗。递增阶段15例未见剂量限制性毒性,选定800 mg为II期推荐剂量;扩展阶段18例高级别治疗相关不良事件少见。推荐剂量组24例确认影像学缓解率54%、临床获益率75%。
要点
- 维奈克拉联合他莫昔芬在ER和BCL2阳性转移性乳腺癌中安全性可耐受。
- 递增阶段未观察到剂量限制性毒性,800 mg被选为II期推荐剂量。
- 推荐剂量组确认影像学缓解率54%,临床获益率75%。
核心结论
- 维奈克拉联合内分泌治疗在ER和BCL2阳性转移性乳腺癌中安全性可耐受,并表现出显著活性。
- 这些发现支持对BCL2阳性肿瘤患者进一步研究联合治疗。
研究设计与样本
- Ib期3+3剂量递增与扩展研究,纳入33例ER和BCL2阳性转移性乳腺癌患者,既往治疗方案数均值2(范围0-8)。
- 递增阶段15例接受每日他莫昔芬20 mg联合维奈克拉200-800 mg;扩展阶段18例。
主要发现
- 递增阶段除无并发症的靶向性淋巴细胞减少外,未观察到剂量限制性毒性或高级别不良事件,800 mg被选为II期推荐剂量。
- 扩展阶段高级别治疗相关不良事件少见。
- 推荐剂量组24例确认影像学缓解率为54%,临床获益率为75%。
- 治疗反应在4周时被FDG-PET代谢反应预先提示,并与循环肿瘤DNA的动态变化相关。
- 10例血浆检出ESR1突变的患者中观察到影像学缓解率40%、临床获益率70%。
关键数值与推荐
- II期推荐剂量为维奈克拉800 mg联合他莫昔芬每日20 mg。
- 推荐剂量组24例确认影像学缓解率54%,临床获益率75%。
- 血浆检出ESR1突变的10例患者影像学缓解率40%,临床获益率70%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venetoclax, a potent and selective BCL2 inhibitor, synergizes with endocrine therapy in preclinical models of ER-positive breast cancer. Using a phase Ib 3 + 3 dose-escalation and expansion study design, 33 patients with ER and BCL2-positive metastatic disease (mean prior regimens, 2; range, 0-8) were treated with daily tamoxifen (20 mg) and venetoclax (200-800 mg). Apart from uncomplicated "on-target" lymphopenia, no dose-limiting toxicities or high-grade adverse events were observed in the escalation phase (15 patients), and 800 mg was selected as the recommended phase II dose (RP2D). In the expansion phase (18 patients), few high-grade treatment-related adverse events were observed. For 24 patients treated at the RP2D, the confirmed radiologic response rate was 54% and the clinical benefit rate was 75%. Treatment responses were preempted by metabolic responses (FDG-PET) at 4 weeks and correlated with serial changes in circulating tumor DNA. Radiologic responses (40%) and clinical benefit (70%) were observed in 10 patients with plasma-detected ESR1 mutations. SIGNIFICANCE: In the first clinical study to evaluate venetoclax in a solid tumor, we demonstrate that combining venetoclax with endocrine therapy has a tolerable safety profile and elicits notable activity in ER and BCL2-positive metastatic breast cancer. These findings support further investigation of combination therapy for patients with BCL2-positive tumors.See related commentary by Drago et al., p. 323.This article is highlighted in the In This Issue feature, p. 305.
引用
- Lok SW, Whittle JR, Vaillant F, et al. A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. Cancer Discov. 2018. PMID: 30518523. doi:10.1158/2159-8290.CD-18-1151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。